Symptoms of insomnia can be treated with several different drugs, but be aware of side effects.
THE NATIONAL SLEEP FOUNDATION recommends that healthy adults sleep seven to nine hours per day. However, many people aren't getting the sleep they need. The Centers for Disease Control and Prevention recently reported that 30% of workers sleep less than six hours per day.
Many different situations can lead to short or interrupted sleep, including predisposing factors such as anxiety, depression and worry about sleep; precipitating factors such as stressful life events, medical or psychiatric illness; shift work; and prescription or nonprescription drugs.
MEDICATIONS TO TREAT INSOMNIA
More recently, a class of medications called benzodiazepine receptor agonists has been developed. They include Ambien (zolpidem), Lunesta (eszopiclone), and Sonata (zaleplon).
"Benzodiazepine receptor agonists, benzodiazepines, the melatonin agonist ramelteon and low doses of the antidepressant doxepin are effective and generally safe for treatment of insomnia," says Mark Abramowicz, MD, editor-in-chief of The Medical Letter on Drugs and Therapeutics, a non-profit newsletter that critically appraises drugs.
The benzodiazepine receptor agonists are not structural benzodiazepines, but bind to benzodiazepine receptors. All act rapidly to decrease sleep latency and do not affect deep sleep; the primary differences between them are in their duration of action.
"However, these agents may impair performance in the morning, including driving," says Dr. Abramowicz. "Complex sleep-related behaviors may occur without conscious awareness."
Over-the-counter sleep aids containing antihistamines such as Benadryl (diphenhydramine) are widely available.
"Over-the-counter antihistamines marketed as sleep aids are not recommended," he says. "They can cause next-day sedation, impairment of performance skills such as driving, and troublesome anticholinergic [dry eye and/or dry mouth] effects."
A wide variety of psychiatric medications, are commonly prescribed for insomnia even though they are not FDA-approved for this condition. The most common are antidepressants such as trazodone (Desyrel, and others), mirtazapine (Remeron) or amitriptyline (Elavil, and others).
"There is little evidence that these agents are effective in treating insomnia not associated with depression," Dr. Abramowicz says.
David Calabrese of OptumRx Talks New Role, Market Insulin Prices and Other Topics 'On His Mind'
April 13th 2023In this month’s episode of the "What's On Your Mind podcast," Peter Wehrwein, managing editor of MHE connects with the now Chief Clinical Officer of OptumRx Integrated Pharmacies, David Calabrese. In this conversation, David touches on his transition in January as OptumRx’s former chief pharmacy officer and market president of health plans and PBMs to his new role as Chief Clinical Officer where he now focuses more on things such as specialty pharmacy to home delivery — with an overall goal of creating whole-patient care. Throughout the conversation, Calabrese also touched on the market’s hot topic of insulin prices and behavioral health services within the OptumRx community, among other topics.
Listen
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
Listen
Upended: Can PBM Transparency Succeed?
March 6th 2024Simmering tensions in the pharmacy benefit management (PBM) industry have turned into fault lines. The PBMs challenging the "big three" have formed a trade association. Purchaser coalitions want change. The head of the industry's trade group says inherent marketplace friction has spilled over into political friction.
Read More
Florida Gets the OK. But Will Drug Importation from Canada Actually Happen?
March 5th 2024Canadian health officials warn that maintaining a drug supply for Canadians is their priority. The staunch opposition of the U.S. pharmaceutical industry may also be an obstacle to imports from north of the border.
Read More